Novartis's Cosentyx Fails To EXCEED Humira in PsA
'Narrowly Missed' Statistical Significance
Executive Summary
The Swiss major's immunology head tells Scrip that while Cosentyx was unable to beat Humira on the 20% improvement scale for symptoms in psoriatic arthritis patients, the totality of the data from the EXCEED study should sway clinicians to use the IL-17 inhibitor as a first-line treatment.